Condition: Rectal Cancer · Sponsor: University Hospital Tuebingen
The goal of this clinical trial is to evaluate the efficacy of deep regional hyperthermia in the context of radiochemotherapy followed by consolidation chemotherapy in locally advanced rectal cancer. Questions it aims to answer are: * Can surgery be avoided if the tumor completely regresses? * How high is the Local re-growth rate * Is the treatment safe? * Assessment of the Quality of life * Rate of sphincter-sparing surgery * Pathological staging, tumor downstaging * Assessment of continence during the course of therapy Participants will: Undergo radiochemotherapy with or without addition of hyperthermia (50:50 randomisation) followed by standard consolidation chemotherapy. After treatment response evaluation surgery or non-operative management takes place.
This description comes directly from the study's public registry record.
Cihan Gani, MD, Prof. Dr. · +49 7071 29-82165 · cihan.gani@med.uni-tuebingen.de
Barbara Gehler, MD, Dr. · +49 7071 29-82165 · barbara.gehler@med.uni-tuebingen.de
Always discuss trial participation with your own doctor first.
| University Hospital | Tübingen, Baden-Wurttemberg, Germany | Recruiting |
| Universitätsklinikum Tübingen | Tübingen, Baden-Wurttemberg, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06831981